VU University Medical Center
Amsterdam, 1081 HV, Netherlands
NCT Number: NCT02455180
The purpose of this study is to determine the pharmacokinetic properties of two different dosage regimens of intravenous vitamin C in patients admitted to the Intensive Care Unit with life-threatening illness.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Amsterdam, 1081 HV, Netherlands
Rationale:
Critically ill patients with trauma or sepsis exhibit a high degree of vitamin C deficiency at ICU admission and vitamin C plasma concentrations decrease even more during the first three days of admission. Vitamin C is a natural anti-oxidant and crucial for endothelial and organ protection
Objective:
To determine the pharmacokinetics of two high dose regimens of intravenous vitamin C in critically ill patients, in particular the attained plasma concentration and the fraction retained in the body and excreted in urine.
Study design:
Prospective randomized controlled pharmacokinetic intervention study
Study population:
Adult critically ill patients admitted to the ICU of the VU University Medical Center, Amsterdam, with sepsis or SIRS after major surgery or trauma with a non-neurological sequential organ failure (SOFA) score >6 and an expected length of ICU stay of >96 hours.
Intervention (if applicable):
Patients will receive either 2 or 10 gram/day vitamin C intravenously twice daily for two days in bolus or continuous infusion.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
Other names: Vitamin C
Time frame: Baseline (before intervention), thereafter at 1, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours after first intervention
Time frame: 0-12hours after first intervention; 36-48 hours after first intervention
Time frame: 0-12hours after first intervention; 36-48 hours after first intervention
Time frame: 0, 24 and 72 hours after first intervention
Time frame: 0 and 24 hours after first intervention
Time frame: 0, 12, 24, 48, 72 and 96 hours after first intervention
Time frame: 0, 4, 24, 72 hours after first intervention
Time frame: 0, 24, 48, 72, 95 after first intervention
Time frame: 0, 24, 48, 72, 95 after first intervention
Amsterdam UMC, location VUmc
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00133978
Critical Illness, Disease Attributes
Aurora, Colorado, United States
View Trial DetailsNCT03345992
Bacterial Infections, Bacterial Infections and Mycoses
Brussels, Belgium
View Trial DetailsNCT00257231
Burns, Inflammation
Denver, Colorado, United States
View Trial DetailsNCT00257244
Burns, Inflammation
Maywood, Illinois, United States
View Trial Details